000			a
999			_c20625 _d20625
003			OSt
005			20240119162929.0
008			240119b xxu||||| |||| 00| 0 eng d
040			_aAIKTC-KRRC _cAIKTC-KRRC
100			_922834 _aSaleh, Naser Hameed
245			_aStudy of hesperetin effect on modulating transcription levels of MLH1 and MSH2 genes in SKBR3 breast cancer cell line
250			_aVol.14(4), Oct-Dec
260			_aMumbai _bWolter Kluwer _c2023
300			_a338-344p.
520			_aHesperetin (HSP), a flavonoid, has been validated to modify gene expression and function as an epigenetic agent to stop the development of breast carcinoma cells. HSP was investigated in this research to evaluate the expression of the MLH1 and MSH2 genes in cancerous breast cell lines (SKBR3) and healthy cell lines (MCF-11A) after exposure to different dosages (200, 400, and 600 µM/mL) of HSP. After 48 h of exposure, SKBR3's half-maximal inhibitory concentration was 289.6 µM/mL and MCF-10A's was 855.4 µM/mL. The research found that increasing HSP concentrations were closely correlated with an increase in MLH1 gene levels in the SKBR3 cell line, as shown by median and percentile values. HSP therapy caused the MLH1 gene expression to substantially vary in different groups, and in the SKBR3 cell line, MSH2 gene expressions were elevated in a dose-escalating manner. Moreover, HSP also raised the number of apoptotic cells, with the fraction of apoptotic cells escalating substantially at doses of 400 and 600 µM/mL. The outcomes suggested that HSP has the potential to be utilized as a therapeutic intervention for breast cancer, as it can induce apoptosis and reduce cell viability.
650		0	_94639 _aPHARMACEUTICS
700			_922835 _aAl-Khafaji, Ahmed Salim Kadhim
773	0		_x2231-4040 _tJournal of advanced pharmaceutical technology and research
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10723173/?report=classic _yClick here
942			_2ddc _cAR